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1 INTRODUCTION  1 
Red cell transfusion has an important role in the management of sickle cell disease 2 
(SCD) in both emergency and elective settings. However, because of insufficient 3 
randomised data, it is not always clear when or how to use red cell transfusion. A 4 
companion BCSH guideline addressed general principles of transfusion practice in 5 
SCD (Davis et al…..). The present guideline examines current available evidence on 6 
indications for transfusion in SCD. This may not be appropriate for all clinical 7 
scenarios and clinical decisions must be based on individual patient considerations. 8 
In both guidelines, the term sickle cell disease refers to all genotypes of the disease, 9 
and sickle cell anaemia to the homozygous state (SS).   10 
 11 
2 METHODS  12 
The writing group was selected by the BCSH General Haematology and Transfusion 13 
Task Forces with input from other experts in Haemoglobinopathy. MEDLINE and 14 
EMBASE were searched systematically for publications from 1960 to 2015 using a 15 
variety of key words. Opinions were also sought from experienced haematologists 16 
with a special interest in the care of SCD patients.  The guideline was reviewed by 17 
the members of the General Haematology Task Force of the BCSH prior to being 18 
sent to a sounding board of approximately 50 UK haematologists, the BCSH and the 19 
BSH Committee. Comments were incorporated where appropriate. The Grading of 20 
Recommendations Assessment, Development and Evaluation (GRADE) 21 
nomenclature was used to evaluate levels of evidence and to assess the strength of 22 
recommendations. The GRADE criteria are specified in the BCSH guidance pack 23 
http://www.bcshguidelines.com/BCSH_PROCESS/EVIDENCE_LEVELS_AND_GRA24 
DES_OF_RECOMMENDATION/43_GRADE.html and the GRADE working group 25 











Key recommendations  1 
Consideration of sickle cell patients for transfusion, particularly long-term 2 
regimens, should weigh up the potential benefits against potential risks (Grade 3 
1C).   4 
 5 
Cerebrovascular disease: 6 
 Regular transfusion to maintain HbS <30% should be offered as initial 7 
treatment to children with SS or S/βo thalassaemia aged 2-16 years judged to 8 
be at high risk for a first stroke on the basis of Transcranial Doppler 9 
ultrasonography (TCD) (Grade 1A). 10 
 11 
Hydroxycarbamide treatment should be considered for the primary prevention 12 
of stroke in children with sickle cell anaemia and high TCD velocities but not 13 
severe Magnetic Resonance Angiography (MRA)-defined cerebral 14 
vasculopathy after an initial period of transfusions (Grade 1A). The duration of 15 
the initial period of transfusion should be tailored to the individual patient but 16 
should be for a minimum of 1 year; the transition to hydroxycarbamide should 17 
be done gradually and transfusion should be withdrawn after the 18 
hydroxycarbamide has been escalated to the maximum tolerated dose. 19 
 20 
Regular transfusion to maintain HbS <30% effectively reduces the incidence of 21 
recurrence of cerebral infarction (defined as a stroke or a new or enlarged 22 
silent cerebral infarct) in children with sickle cell anaemia and S/βo 23 
thalassaemia aged 5-15 years. Treatment options including transfusion should 24 
be discussed with families of children who are found to have silent cerebral 25 
infarcts. Transfusion should be offered to children who are identified to be at 26 
greatest risk for recurrence of infarction after discussion of its benefits and 27 
risks (Grade 1A) 28 
 29 
Long-term transfusion to maintain HbS <30% is recommended for the 30 
prevention of recurrent ischaemic stroke due to sickle cell disease in both 31 




children and adults (Grade 1B)  1 
 2 
Adults or children who present with signs or symptoms suggestive of acute 3 
ischaemic stroke should be transfused without any delay to maintain HbS 4 
<30% pending further investigation. Those with confirmed stroke due to sickle 5 
cell disease should continue regular transfusions long-term (Grade 1B). 6 
 7 
Surgery 8 
Preoperative transfusion is recommended for SS patients undergoing medium-9 
risk surgery (e.g. abdominal, tonsillectomy, orthopaedic) (Grade 1A). 10 
 11 
Preoperative transfusion is recommended for SC patients undergoing 12 
medium-risk surgery (e.g. abdominal, tonsillectomy, orthopaedic) (Grade 1C). 13 
 14 
Transfusion is recommended for sickle cell patients of all genotypes  requiring 15 
high-risk surgery (e.g. cardiovascular, brain) (Grade 1C). 16 
 17 
All sickle cell patients with other genotypes undergoing surgery should be 18 
individually assessed taking into account previous history and complexity of 19 
surgery, and a management plan should be formulated to include the need for 20 
transfusion (Grade 1C) 21 
 22 
Particular care should be taken to ensure that all aspects of perioperative care 23 
including oxygenation, hydration, warmth and anaesthetic and surgical 24 
technique are optimised in all sickle cell patients undergoing surgery (Grade 25 
1C). 26 
 27 
For patients requiring emergency surgery, the urgency and complexity of the 28 
procedure should be taken into account in the timing of perioperative 29 
transfusion.  Simple transfusion should be given preoperatively if Hb <90 g/l 30 
provided this will not result in undue delay to surgery. If transfusion is likely to 31 
cause an unacceptable delay to surgery, it is reasonable to proceed to surgery 32 




while arranging to transfuse the patient intra- or post-operatively if necessary 1 
(Grade 1D). 2 
 3 
Acutely ill patients 4 
Transfusion (excahnge or top up?)  is recommended and may be life-saving in 5 
acute sickle complications such as splenic sequestration, hepatic 6 
sequestration, aplastic crisis and severe acute chest syndrome (Grade 1B).  7 
 8 
Transfusion should be considered in the unwell patient with acute multi-organ 9 
failure,  mesenteric syndrome (Grade 1C) and patients with severe sepsis 10 
(Grade 2C). Such cases should be discussed with the specialist 11 
haemoglobinopathy team (SHT). 12 
 13 
Transfusion for other causes of acute anaemia requires individual assessment 14 
and should be discussed with the SHT.  Transfusion may be given by simple 15 
transfusion (top up) or exchange depending on clinical severity under the 16 
guidance of the SHT (Grade 2C).  17 
 18 
Pregnancy 19 
Transfusion is not routinely required for uncomplicated singleton pregnancies. 20 
. 21 
(Grade 1B). 22 
 23 
Transfusion should be considered in women with previous or current serious 24 
medical, obstetric or fetal problems, women with worsening anaemia, those on 25 
long-term transfusions for stroke prevention or for amelioration of severe 26 
sickle complications, women on hydroxycarbamide because of severe disease 27 
and those with multiple pregnancy (Grade 1C). 28 
 29 
Amelioration of severe disease 30 
In selected patients with severe disease, blood transfusion can be effective in 31 
ameliorating disease, resulting in reduction in hospital bed days.  32 




Hydroxycarbamide is recommended as first line treatment for prevention of 1 
recurrent acute chest syndrome or repeated painful episodes associated with 2 
chest syndrome (Grade 1A). Regular transfusion should be considered for 3 
patients failing this treatment or for whom hydroxycarbamide is 4 
contraindicated or not acceptable (Grade 1B). 5 
 6 
Other indications 7 
Transfusion is not recommended to treat steady state anaemia provided that 8 
Hb has not fallen over a period of time to symptomatic levels (e.g. with 9 
developing chronic kidney disease) (Grade 1C).  10 
 11 
There is no evidence that transfusion shortens the duration of a painful crisis.   12 
Transfusion is not recommended in uncomplicated painful crises but should 13 
be considered if there is a substantial drop in Hb  from baseline (e.g. > 20g/l or 14 
to Hb <50g/l), haemodynamic compromise or concern about impending critical 15 
organ complications (Grade 1C).  16 
 17 
The benefit of transfusion to relieve established acute priapism has not been 18 
shown in randomised controlled trials. Many patients require a shunt or 19 
drainage procedure under general anaesthesia which may require a 20 
transfusion. Such cases should be discussed with the SHT (Grade 2C). 21 
 22 
Transfusion has been shown to reduce the incidence of symptomatic 23 
avascular necrosis in children receiving regular transfusions to maintain HbS 24 
<30% for prevention of recurrence of cerebral infarction (Grade 1A). However, 25 
there is no consensus on the use of transfusion for the sole purpose of 26 
preventing this complication in routine practice.  27 
 28 
Where transfusion is considered for indications where there is insufficient 29 
evidence for its benefit (e.g. leg ulcers, pulmonary hypertension, end stage 30 
renal or liver disease, progressive sickle cell retinopathy), a full risk-benefit 31 
assessment should be carried out in liaison with the SHT and each case 32 




should be considered on its own merits (Grade 2C).  1 
 2 
 3 
3 INDICATIONS FOR TRANSFUSION IN SICKLE CELL DISEASE   4 
The indications for red cell transfusion in SCD range from those in which transfusion 5 
can be strongly recommended to those where its use is unproven or controversial. A 6 
case-by-case detailed analysis of risk and benefit of red cell transfusion should be 7 
undertaken for unproven or controversial indications. 8 
 9 
The indications can be broadly categorised into conditions in which correction of 10 
anaemia is the main goal and those where reduction of sickle haemoglobin (HbS) 11 
may be more appropriate (see Table 1). In both categories, transfusion is either 12 
performed acutely, as part of the management of an acute complication of SCD, or 13 
electively for the prevention or management of disease complications.  Elective 14 
transfusions may be one-off (e.g. preoperative) or be part of a long-term transfusion 15 
programme.   16 
 17 
The decision to transfuse any patient with SCD should be taken by senior medical 18 
staff, ideally at consultant level  with the appropriate experience. Long-term elective 19 
transfusions should usually be initiated by or in consultation with a specialist 20 
haemoglobinopathy team (SHT). 21 
 22 
It should be recognised that the low steady state Hb in SCD is the result of the low 23 
oxygen affinity of haemoglobin S and is therefore not in itself an indication or 24 
transfusion. 25 
 26 
4. INDICATIONS FOR EMERGENCY TRANSFUSION  27 
 28 
4.1. Emergency transfusion with the primary aim of correcting acute anaemia 29 
 30 
4.1.1 Ascertaining the cause of anaemia 31 




Acute anaemia in SCD has been defined as a fall in haemoglobin ≥20 g/l below the 1 
steady state value (Emond, et al 1985, NHLBI 2014). Understanding the cause of the 2 
anaemia is essential for appropriate management. Causes broadly include: 3 
decreased production, sequestration and increased haemolysis.  Initial assessment 4 
should include: history of recent transfusion, haemodynamic status, spleen and liver 5 
size, full blood count and reticulocyte count.  Any decision to transfuse should take 6 
into consideration the likely cause, haemodynamic status and degree of anaemia 7 
relative to baseline. 8 
 9 
4.1.2 Aplastic crisis 10 
Aplastic crisis should be suspected in patients with acute exacerbation of steady 11 
state anaemia with reticulocytopenia and is usually due to infection with human 12 
erythrovirus (formerly parvovirus) B19 (Goldstein, et al 1987, Pattison, et al 1981, 13 
Serjeant, et al 1993, Serjeant, et al 1981). Anaemia is usually severe with a mean 14 
fall of approximately 40 g/l below steady state values (Goldstein, et al 1987, 15 
Serjeant, et al 2001).  16 
 17 
Simple transfusion to steady state level is usually all that is required to maintain the 18 
oxygen carrying capacity of blood (Goldstein, et al 1987, Serjeant, et al 1993, Smith-19 
Whitley, et al 2004). Spontaneous resumption of erythropoiesis tends to occur within 20 
7-10 days of aplasia (Anderson, et al 1985), restoring the Hb to the steady state 21 
value. Most patients will be close to spontaneous marrow recovery at the time of 22 
clinical presentation with development of reticulocytosis and recovery of Hb 23 
occurring <7 days from presentation (Serjeant, et al 1993).  24 
 25 
Erythrovirus B19 may occasionally present with  serious and potentially life-26 
threatening complications including acute splenic sequestration, acute chest 27 
syndrome (ACS) (Lowenthal, et al 1996, Smith-Whitley, et al 2004) or acute 28 
neurological syndromes including stroke (Balkaran, et al 1992, Wierenga, et al 29 
2001). In such cases, exchange transfusion may be more appropriate. 30 
 31 
4.1.3 Acute splenic sequestration 32 




Acute splenic sequestration is characterised by an acute fall in Hb ≥20 g/l, 1 
reticulocytosis and sudden splenic enlargement (Emond, et al 1985), and in severe 2 
cases may result in circulatory failure and even death (Emond, et al 1985,Rogers, et 3 
al 1978). Although splenic sequestration typically occurs in the first 5 years of life 4 
(Topley, et al 1981) before the spleen has spontaneously infarcted, it may 5 
occasionally occur later particularly in those with milder disease such as SC disease 6 
in whom splenic infarction may not occur until later in life (Aslam, et al 2005, 7 
Roshkow and Sanders 1990). Immediate management consists of simple  8 
transfusion to raise the Hb to steady state level (Emond, et al 1985). Transfusion 9 
with emergency (O Rh (D) negative) or ABO- and Rh (D)-specific uncrossmatched 10 
blood may occasionally be necessary to treat shock and anaemia in extremis. In 11 
many cases, however, cautious transfusion of small red cell volumes to raise the 12 
haemoglobin to the steady state level is sufficient to reverse the process and correct 13 
hypovolaemia and anaemia. Transfusion of large volumes of red cells should be 14 
avoided due to the risk of hyperviscosity when sequestered red cells return to the 15 
circulation (Josephson, et al 2007, Kinney, et al 1990, Quirolo 2010, Wanko and 16 
Telen 2005)  17 
 18 
All patients with previous splenic sequestration should be discussed with the SHT. 19 
There is a high recurrence rate (Brousse, et al 2012, Emond, et al 1985) and 20 
splenectomy is advised in patients who have recurrent episodes (two or more). 21 
Splenectomy is not associated with an increased long-term risk of bacteraemic 22 
episodes or death (Wright, et al 1999). Regular transfusion to maintain HbS <30% 23 
did not reduce the risk of recurrence or need for splenectomy after splenic 24 
sequestration compared to clinical observation in a retrospective observational study 25 
(Kinney, et al 1990).  26 
 27 
4.1.4 Acute hepatic sequestration 28 
Acute hepatic sequestration presents with acute hepatic enlargement associated 29 
with a fall in Hb ≥20 g/l and rise in the reticulocyte count. It usually responds to 30 
simple  transfusion or exchange transfusion (Gutteridge, et al 1985, Hatton, et al 31 
1985); spontaneous resolution has been reported (Hatton, et al 1985). As in acute 32 




splenic sequestration, the return of sequestered red cells into the circulation may 1 
cause acute hyperviscosity (Lee and Chu 1996) and cautious transfusion of small 2 
volumes of red cells is recommended. 3 
 4 
4.1.5 Delayed haemolytic transfusion reaction (classical and hyperhaemolysis 5 
syndrome) 6 
A delayed haemolytic transfusion reaction (DHTR) (classical or hyperhaemolysis)  7 
must be strongly suspected in patients presenting with acute anaemia with/without 8 
pain typical of vaso-occlusive crisis following a recent transfusion (King, et al 1997, 9 
Milner, et al 1985, Petz, et al 1997). Hyperhaemolysis may be missed because it is 10 
assumed that the patient’s symptoms are due entirely to a painful crisis. The 11 
investigation and management of these two syndromes have been described in the 12 
companion guideline (Davis et al, ……..) 13 
 14 
 All cases of DHTR and hyperhaemolysis should be discussed with the SHT both for 15 
advice on management and because of the long-term implications of 16 
alloimmunisation and risk of hyperhaemolysis recurrence.   17 
 18 
4.1.6 Increased haemolysis during painful crises 19 
Transfusion is not recommended in uncomplicated painful crises. Although Hb often 20 
drops to slightly below steady state levels, transfusion is typically not required and 21 
Hb will return to baseline as the crisis abates.  Transfusion may be indicated if there 22 
is a substantial drop in Hb from baseline (e.g. >20 g/l or Hb<50 g/l), haemodynamic 23 
compromise or concern about impending critical organ complications (see below).  24 
 25 
4.1.7 Other causes of exacerbation of anaemia 26 
An acute decline in Hb due to haemolysis is common in acute sickle complications 27 
such as acute chest syndrome (ACS)  (Howard, et al 2015) and acute multi-organ 28 
failure syndrome (Hassell, et al 1994). The role of transfusion in these two 29 
syndromes is described in sections 4.2.1 and 4.2.3. Urgent transfusion is indicated 30 
for acute blood loss.  31 
 32 




Severe anaemia during hydroxycarbamide therapy requiring transfusion is usually 1 
due to an acute intercurrent illness such as acute splenic sequestration, aplastic 2 
crisis or ACS  rather than the myelosuppressive effects of the drug  (Gulbis, et al 3 
2005, Hankins, et al 2005b, Kinney, et al 1999, Scott, et al 1996, Wang, et al 2001).  4 
The effects of myelosuppression are usually reversible rapidly upon reduction of the 5 
dose or temporary cessation of hydroxycarbamide but full recovery may not occur for 6 
several weeks (Hankins, et al 2005b, Wang, et al 2001). 7 
 8 
In patients with sickle cell nephropathy, a slow decline of haemoglobin concentration 9 
occurs as the renal disease progresses and the anaemia may be severe enough to 10 
compromise cardiovascular function (Serjeant 2001). 11 
 12 
Recommendations 13 
Simple transfusion to steady state haemoglobin concentration is indicated for 14 
patients with acute exacerbation of anaemia as a result of aplastic crisis or 15 
sequestration crisis (Grade 1B).   16 
 17 
Transfusion is not recommended in uncomplicated vaso-occlusive crisis but 18 
should be considered if there is worsening anaemia, haemodynamic 19 
compromise or concern about impending critical organ complications (Grade 20 
1C). 21 
 22 
Transfusion for other causes of acute anaemia requires individual assessment 23 
and should be discussed with the specialist haemoglobinopathy team (SHT) 24 
(Grade 1C).   25 
  26 
 27 
4.2 Emergency transfusion with the primary aim of reducing HbS in relation 28 
to HbA 29 
Transfusion to reduce the %HbS is indicated where there is evidence of acute critical 30 
organ complications, especially acute chest syndrome (ACS) and ischaemic stroke.   31 
 32 




4.2.1 Acute chest syndrome (ACS) 1 
ACS usually develops during a painful crisis and should be suspected in patients 2 
presenting with fever and/or respiratory symptoms, together with clinical signs of 3 
lung consolidation (Howard, et al 2015). Early recognition of ACS and intervention 4 
with blood transfusion can be life-saving.   5 
 6 
ACS can develop rapidly and progress to acute respiratory failure within a few hours. 7 
It is advisable to plan to have blood available if early signs of ACS occur, even if 8 
other measures subsequently render transfusion unnecessary.  Both simple and 9 
exchange transfusion rapidly improved oxygenation with similar efficacy in non-10 
randomised studies (Turner, et al 2009, Vichinsky, et al 2000). A simple transfusion 11 
aiming for a target Hb 100-110 g/l is effective in preventing progression to acute 12 
respiratory failure in patients with mild ACS if it is given early in the illness (Emre, et 13 
al 1995) and should be considered in patients with a PaO2 <9.0 kPa on room air, but 14 
may also be needed at less severe degrees of hypoxaemia, depending on the 15 
individual patient’s history and clinical features, or if the patient’s oxygen 16 
requirements are increasing (Howard, et al 2015). Exchange transfusion is 17 
recommended in patients with features of severe ACS, those who fail to respond to 18 
initial simple  transfusion, or patients with a higher Hb (>90 g/l) where there is little 19 
leeway for  simple  transfusion (Emre, et al 1995, Howard, et al 2015, NHLBI 2014, 20 
Vichinsky, et al 1997).  21 
 22 
There is no evidence as to the optimal %HbS target post-exchange transfusion. In 23 
practice a target of <30–40% is often used, but clinicians should be guided by the 24 
clinical response (Howard, et al 2015). 25 
 26 
Guidelines for the diagnosis and management of ACS are available from the BCSH 27 
(Howard, et al 2015). 28 
 29 
4.2.2 Acute ischaemic stroke  30 
The value of transfusion and the comparative effects of exchange versus simple 31 
transfusion in acute ischaemic stroke have not been evaluated in randomised trials. 32 




Emergency exchange transfusion to reduce HbS to <30% is recommended for acute 1 
ischaemic stroke (NHLBI 2014, RCP 2004, Sickle Cell Society 2008).  Initial simple  2 
transfusion should be given if the stroke has occurred in the context of severe acute 3 
anaemia (e.g. in aplastic crisis) (RCP 2004). Although there are no controlled trials 4 
on the effect of transfusion on the stroke itself, red cell transfusion may potentially 5 
minimise morbidity and mortality by improving perfusion and oxygenation to the 6 
brain, thereby preventing extension of an infarct. There is evidence from a 7 
retrospective cohort study that exchange transfusion for a first overt stroke at the 8 
time of stroke presentation is associated with a lower risk of a subsequent stroke 9 
compared to simple  transfusion (Hulbert, et al 2006). It is important to avoid 10 
hypovolaemia during the procedure and to keep the post-transfusion Hb at a target 11 
of 100 g/l, as a high haematocrit associated with hyperviscosity may worsen the 12 
neurological insult. 13 
 14 
Current pathways for acute stroke care in the UK require adult patients with 15 
suspected stroke to be admitted directly to specialist stroke units (hyperacute stroke 16 
units) (NICE 2008). NHS Trusts must ensure that governance arrangements are in 17 
place to provide specialist haemoglobinopathy care for SCD patients with suspected 18 
stroke who are admitted to hyperacute stroke units so that emergency exchange 19 
transfusion can be provided in a timely manner. Although this model of care has not 20 
been developed for paediatrics, NHS Trusts must develop local protocols with the 21 
collaboration of their SHT so that SCD children with acute stroke can receive 22 
appropriate care, including timely exchange transfusion and specialist neurology 23 
advice (Dick 2010, RCP 2004). 24 
 25 
There are currently no data to support the use of red cell transfusion either in the 26 
acute management of haemorrhagic stroke or to prevent its recurrence and it is 27 
recommended that specialist advice is sought for individual cases. 28 
 29 
4.2.3 Acute multi-organ failure syndrome 30 
This is a severe life-threatening syndrome that may complicate a severe painful 31 
crisis. It is particularly likely to occur in patients with otherwise mild sickle cell 32 




disease and a relatively high haemoglobin concentration.  The patient presents with 1 
multi-organ failure with associated fever, rapid decrements in Hb and platelet count, 2 
non-focal encephalopathy and rhabdomyolysis. The syndrome usually responds to 3 
aggressive exchange transfusion (Hassell, et al 1994) 4 
 5 
 6 
4.2.4 Mesenteric (“girdle”) syndrome 7 
This is a rare severe sequestration syndrome characterised by simultaneous or 8 
consecutive sickling and sequestration in the mesenteric vascular bed, liver and 9 
lungs (Brozovic, et al 1987). Preceding pain in the abdomen, lumbar spine and limbs 10 
is common. Sickling in the abdomen can present with tenderness and rigidity, 11 
mimicking peritonitis and progressing to ileus, with a silent distended abdomen and 12 
dilated loops of bowel on X-ray. Acute chest syndrome frequently develops due to 13 
splinting of the chest wall. Acute exchange blood transfusion is indicated.  14 
 15 
4.2.5 Severe sepsis  16 
Severe sepsis often engenders a vicious circle of tissue hypoxia, acidosis and 17 
sickling. An exchange transfusion or simple  transfusion may be useful in correcting 18 
anaemia, improving microvascular blood flow, improving tissue oxygenation and the 19 
patient’s overall clinical condition (Ohene-Frempong 2001) 20 
 21 
4.2.6 Acute intrahepatic cholestasis 22 
This is a rare and little understood complication that presents with extreme 23 
conjugated and unconjugated hyperbilirubinaemia (relative to the steady state 24 
bilirubin), marked elevation of the alkaline phosphatase and variable rises in 25 
transaminase levels. There is a high mortality from liver failure or bleeding. There is 26 
no established treatment but exchange transfusion appears to be beneficial (Shao 27 
and Orringer 1995). 28 
 29 
4.2.7 Acute priapism 30 
The treatment of priority in acute fulminant priapism is penile aspiration/irrigation 31 
followed by the intracavernosal injection of sympathomimetic drugs if aspiration fails 32 




to resolve the problem (Montague, et al 2003). This initial urological intervention 1 
should not be delayed while a transfusion is arranged. 2 
 3 
Neither simple nor exchange transfusion have been evaluated for acute 4 
management of priapism in randomised controlled trials. Small case series and 5 
literature reviews provide no evidence of amelioration of pain or duration of priapism 6 
once this has been established.  (McCarthy, et al 2000, Merritt, et al 2006). Surgical 7 
management is indicated if initial urological measures are not effective (Montague, et 8 
al 2003). Shunt procedures for the relief of acute priapism require a general 9 
anaesthetic  so that the patient may benefit from transfusion, as with other surgical 10 
procedures (Howard, et al 2013). If patients do not respond to initial shunt 11 
procedures there may be benefit from exchange transfusion to decrease %HbS. 12 
Local hospitals should develop referral pathways so that patients requiring specialist 13 
surgery are transferred promptly to tertiary centres. Such patients must be discussed 14 
with the SHT with regards to possible transfusion pre-operatively.  15 
 16 
Recommendations 17 
Transfusion is recommended in cases of acute chest syndrome (ACS) with 18 
hypoxia. Transfusion may be given by simple or exchange transfusion 19 
depending on clinical severity under the guidance of the SHT (Grade 1B).   20 
  21 
Adults or children with signs or symptoms suggestive of acute ischaemic 22 
stroke should be transfused to sickle haemoglobin (HbS) <30% pending 23 
further investigation. Those with confirmed stroke due to sickle cell disease 24 
should continue regular transfusions indefinitely (Grade 1B). 25 
 26 
Transfusion should be considered in the unwell patient with acute multi-organ 27 
failure, mesenteric syndrome (Grade 1C) and patients with severe sepsis 28 
(Grade 2C). Such cases should be discussed with the SHT.  29 
 30 
The benefit of transfusion to relieve established acute priapism has not been 31 
shown in randomised controlled trials. Many patients require a shunt or 32 




drainage procedure under general anaesthesia, which may require a 1 
transfusion. Such cases should be discussed with the SHT (Grade 2C). 2 
 3 
 4 
5. INDICATIONS FOR CHRONIC TRANSFUSION 5 
The best data to support chronic transfusion programmes are for the primary 6 
prevention of stroke (Adams and Brambilla 2005, Adams, et al 1998) and secondary 7 
prevention of silent cerebral infarcts in paediatric populations (DeBaun, et al 2014). 8 
There is also good evidence for the effectiveness of transfusions in preventing 9 
recurrent stroke in children (Pegelow, et al 1995, Scothorn, et al 2002).  10 
Chronic exchange transfusion has been utilised for a wide variety of indications 11 
including prevention of recurrent vaso-occlusive crises and recurrent chest 12 
syndrome.   In many of these circumstances there is also evidence of benefit of 13 
hydroxycarbamide therapy (Charache, et al 1995, Thornburg, et al 2012) and 14 
chronic transfusion should only be contemplated where hydroxycarbamide is 15 
ineffective or contra-indicated. 16 
Where chronic transfusion is initiated outside the context of paediatric stroke, the 17 
parameters to assess efficacy should be clearly documented and the risks and 18 
benefits for the patient regularly reviewed.  Outcomes of chronic transfusion 19 
programmes should be regularly audited across centres.  Decisions to initiate 20 
chronic transfusion should be made by the SHT. 21 
 22 
5.1 Primary and secondary stroke prevention 23 
Long-term red cell transfusion is the mainstay of treatment for the primary and 24 
secondary prevention of stroke due to SCD. Evidence for the efficacy of transfusion 25 
for primary stroke prevention is available only for children but the principles may be 26 
relevant for adult patients (over 16 years). 27 
 28 
5.1.2 Primary stroke prevention in children with SCD 29 
Regular red cell transfusion to maintain HbS level <30% is indicated for the primary 30 




prevention of stroke in children (2-16 years) with SS or S/βo thalassaemia  with time 1 
averaged mean Transcranial Doppler ultrasonography (TCD) velocities of ≥200 2 
cm/sec in the internal carotid or middle cerebral artery (Stroke Prevention Trial in 3 
Sickle Cell  Anemia study - STOP) (Adams, et al 1998). Regular red cell transfusion 4 
reduced the risk of an initial stroke by 92% (Adams, et al 1998), This was confirmed 5 
in the Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP2) Trial, 6 
where children whose transfusions were discontinued were more likely to have a 7 
stroke or to revert to abnormal TCD velocities than those who continued on regular 8 
transfusion (Adams and Brambilla 2005) 9 
 10 
The role of hydroxycarbamide in  maintaining normal TCD velocities in children 11 
without severe cerebral vasculopathy or prior transient ischaemic attack (TIA) who 12 
have received transfusions for at least one year (mean 4 years) for primary stroke 13 
prevention has recently been investigated in the TCD With Transfusions Changing to 14 
Hydroxyurea (TWiTCH) trial (Ware, et al 2015). In this randomised trial, 15 
hydroxycarbamide at maximum tolerated dose (alternative group) was compared to 16 
standard transfusions (standard group) after patients randomised to 17 
hydroxycarbamide had been slowly weaned off transfusions over 4-9 months. This 18 
trial showed that hydroxycarbamide is non-inferior to transfusions for the 19 
maintenance of TCD velocities and can be used as a substitute to help prevent 20 
primary stroke after discontinuation of initial transfusion therapy.  21 
 22 
The role of transfusion in the management of children with sickle cell anaemia aged 23 
5-15 years (median 10 years) with silent cerebral infarcts was investigated in the 24 
Silent Cerebral Infarct Multi-Center Clinical Trial (SIT) (DeBaun, et al 2014). In this 25 
randomised trial, children with SS or S/βo thalassaemia with silent cerebral infarcts 26 
and normal or conditional TCD velocities were randomised to receive monthly 27 
transfusions to a target Hb of 90 g/l and HbS <30% or standard care (observation 28 
group) for three years. The primary endpoint was  recurrence of infarction, defined 29 
as a stroke, or new or enlarged silent cerebral infarct. The transfused group had a 30 
relative risk reduction of recurrence of infarction of 58% compared to the observation 31 
group; however, this was mainly due to a reduction in stroke incidence rather than a 32 




reduction in silent infarcts by transfusions.  The authors recommended a screening 1 
Magnetic Resonance Imaging (MRI) scan of the brain to identify children who may 2 
benefit from medical or educational intervention. However, MRI is difficult to perform 3 
without sedation in children <7 years old, the age group in which the majority of 4 




Transfusion to maintain HbS <30% should be offered to children at high risk of 9 
stroke following Transcranial Doppler (TCD) screening. Transfusion is the 10 
recommended initial treatment to prevent stroke in such children (Grade 1A). 11 
 12 
Hydroxycarbamide treatment should be considered for the primary prevention 13 
of stroke in children with high TCD velocities but not severe MRA-defined 14 
cerebral vasculopathy after an initial period of transfusion of at least 1 year 15 
(Grade 1A). The duration of the initial period of transfusion should be tailored 16 
to the individual patient; the transition to hydroxycarbamide should be done 17 
gradually and transfusion should be withdrawn after the hydroxycarbamide 18 
has been escalated to the maximum tolerated dose. 19 
 20 
Treatment options including transfusion should be discussed with families of 21 
children who are found to have silent cerebral infarcts. Transfusion should be 22 
offered to children who are identified as being at greatest risk for recurrence 23 
of infarction after discussion of its benefits and risks (Grade 1A) 24 
 25 
5.1.3 Secondary stroke prevention in children with SCD 26 
The risk of recurrent stroke in children with SCD is very high. In a natural history 27 
study of 35 patients with a history of one or more strokes, the recurrence rate was 28 
67% over a 9 year period, with 80% of the recurrent episodes occurring within 36 29 
months of the initial event (Powars, et al 1978).  30 





There have been no randomised trials comparing the use of transfusion to no 2 
intervention for prevention of recurrent stroke in SCD. Several single centre studies 3 
(Balkaran, et al 1992, Lusher, et al 1976, Russell, et al 1984, Sarnaik, et al 1979) 4 
and two multi-centre retrospective studies (Pegelow, et al 1995, Scothorn, et al 5 
2002) all reported a clear benefit of transfusion in reducing the risk of recurrence in 6 
patients who had suffered one or more previous episodes of cerebral infarction.  7 
 8 
In the Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) trial, a non-9 
inferiority trial which compared transfusion to HbS <30% plus chelation with 10 
hydroxycarbamide plus phlebotomy for the composite endpoint of secondary stroke 11 
prevention and improved control of iron overload, there were no cases of recurrent 12 
stroke in the transfused patients compared with 10% in the 13 
hydroxycarbamide/phlebotomy arm (Ware, et al 2012). The trial was closed early 14 
because even though the increased stroke risk in the hydroxycarbamide arm was 15 
within the predicted 12% rate, it was not offset by a reduction in iron overload 16 
through phlebotomy. Therefore, the authors concluded that transfusion and chelation 17 
remain a better way to manage children with sickle cell anaemia, stroke and iron 18 
overload. 19 
 20 
Although the risk of stroke is not completely eliminated by regular transfusions 21 
(Hulbert, et al 2011, Pegelow, et al 1995, Scothorn, et al 2002), transfusions to 22 
maintain HbS <30% remains the recommended intervention to prevent stroke 23 
recurrence in children with SCD.  There is some evidence from a small observational 24 
study that patients on transfusion programmes for secondary stroke prevention may 25 
be maintained on a less rigorous target of HbS <50% with little increased risk of 26 
stroke recurrence, provided they have been neurologically stable for at least 4 years 27 
after the initial stroke (Cohen, et al 1992). 28 
 29 
Recommendation 30 




Long-term transfusion to maintain HbS <30% is recommended for the 1 
prevention of recurrent ischaemic stroke due to sickle cell disease in children 2 
(Grade 1B).  3 
 4 
5.1.4 Primary stroke prevention in adults with SCD 5 
Adults with sickle cell anaemia are at increased  risk of ischaemic and haemorrhagic 6 
stroke; the risk of ischaemic stroke is highest after the age of 30 years, whereas 7 
haemorrhagic stroke is most common in the 20-29 year age group (Ohene-8 
Frempong, et al 1998). TCD has not been validated in adults and there is currently 9 
no tool for systematically assessing stroke risk. Studies to evaluate the efficacy of 10 
transfusion for primary stroke prevention in defined adult SCD populations have not 11 
been undertaken. 12 
 13 
5.1.5 Secondary stroke prevention in adults with SCD 14 
Whilst neurological events such as transient ischaemic attack or seizures may be 15 
the initial presentation of sickle cell cerebrovascular disease, adults experiencing 16 
such episodes should be fully investigated for other possible causes (e.g. atrial 17 
fibrillation, carotid artery stenosis). Data on transfusion for secondary stroke 18 
prevention in adult SCD is limited.  An observational study (Powars, et al 1978) 19 
which included some adult subjects strongly suggests that the risk of further strokes 20 
is likely to be high without intervention. Current practice is to perform chronic 21 
transfusions in adults who have suffered a stroke attributable to SCD (NHLBI 2014, 22 
Sickle Cell Society 2008).  23 
 24 
Recommendation 25 
Long-term transfusion to maintain HbS <30% is recommended for the 26 
prevention of recurrent ischaemic stroke due to sickle cell disease in adults 27 
(Grade 1B).  28 
 29 




5.1.6 Duration of transfusions for stroke prevention 1 
The optimal duration of transfusion is uncertain. Data from the STOP 2 trial indicated 2 
that patients who were maintained on transfusion for a follow up period of 65 months 3 
for primary stroke prevention had a 93% lower stroke risk than patients who 4 
discontinued transfusions after 30 months (Adams and Brambilla 2005).  The results 5 
of the TWiTCH trial show that hydroxycarbamide is efficacious and non-inferior to 6 
blood transfusions for primary stroke prevention in children without severe cerebral 7 
vasculopathy or prior TIA who have been on transfusion for at least a year (mean 4 8 
years) (Ware, et al 2015). However, the trial did not establish the optimal duration of 9 
transfusions prior to the switchover to hydroxycarbamide. Therefore, we suggest 10 
that the duration of this initial period of transfusions is assessed on a case by case 11 
basis.  12 
 13 
For patients who have had a stroke, the risk of recurrent stroke is highest in the first 14 
three years after the initial event (Balkaran, et al 1992, Pegelow, et al 1995, Powars, 15 
et al 1978, Russell, et al 1984), suggesting that maintaining a HbS level <30% is 16 
especially important during this period. The benefits of transfusions beyond this 17 
period are debatable. Recurrent stroke has been reported within 12 months of 18 
prospectively stopping transfusions in 5 out of 10 children who had been on a 19 
transfusion programme for as long as 9.5 years (Wang, et al 1991). Therefore, 20 
transfusion for secondary stroke prevention may need to continue indefinitely 21 
(NHLBI 2014, Sickle Cell Society 2008), but the decision to continue transfusions 22 
should be tailored to the needs of individual patients; it should be regularly reviewed 23 
and risk/benefit considerations must be discussed with the patient and/or parents. It 24 
has been suggested that where the stroke has occurred in the context of acute 25 
illness (e.g. aplastic crisis), transfusions may be discontinued after two years if 26 
repeat vascular imaging is normal at that time (RCP 2004) 27 
 28 
 Recommendation 29 
Transfusion is the recommended initial treatment of choice for children at high 30 
risk of stroke based on TCD screening (Grade 1A). Provided there is no 31 




concomitant severe cerebral vasculopathy or prior history of TIA, 1 
hydroxycarbamide may be offered to such children after at least one year of 2 
transfusions (Grade 1A) but the exact duration of transfusions should be 3 
tailored to the individual patient.  4 
 5 
Long-term transfusion should be offered to children and adults who have 6 
suffered a previous ischaemic stroke due to sickle cell disease (Grade 1B). 7 
 8 
5.2 Recurrent acute chest syndrome 9 
ACS is a marker of SCD severity, being a risk factor for early death in SS patients 10 
>20 years (Castro, et al 1994, Platt, et al 1994) and 44% of patients will have 11 
recurrent episodes (Castro, et al 1994). Evidence suggests that chronic transfusion 12 
therapy is effective in reducing incidence and hospitalisation due to ACS (Hankins, 13 
et al 2005a, Miller, et al 2001, Styles and Vichinsky 1994). In the SIT trial, ACS was 14 
significantly reduced in comparison with untransfused patients with an incidence rate 15 
ratio of 0.13 (DeBaun, et al 2014). However, since there is a clear benefit of 16 
hydroxycarbamide for ACS prevention (Charache, et al 1995, Thornburg, et al 17 




Hydroxycarbamide is recommended as first line treatment for recurrent acute 22 
chest syndrome or repeated painful episodes. Regular transfusion should be 23 
considered for patients failing this treatment or for whom it is contraindicated 24 
(Grade 1B). 25 
 26 
5.3 Frequent painful crises  27 
The frequency of sickle cell painful crises is a marker of disease severity; SS 28 
patients who are admitted to hospital ≥3 times a year because of vaso-occlusive 29 
crises are at increased risk of early death (Platt, et al 1991). Prolonged 30 




hospitalisations and high readmission rates are also associated with a higher 1 
mortality (Ballas and Lusardi 2005, Houston-Yu, et al 2003).  2 
 3 
Long-term transfusion may be of benefit in patients with recurrent painful crises. In a 4 
retrospective study, long-term blood transfusion significantly reduced the hospital 5 
admission frequency for vaso-occlusive crises from 2.20 to 0.21 per patient per year 6 
(Styles and Vichinsky 1994). In the STOP trial, the hospital admission rate for vaso-7 
occlusive crises in chronically transfused patients was significantly less than for 8 
patients on standard care (9.7 v 27.1 events per 100 patient years) (Miller, et al 9 
2001). In the SIT trial, incidence rates of painful crises were significantly reduced by 10 
transfusion with an incidence rate ratio of 0.41 (DeBaun, et al 2014).  11 
 12 
However, hydroxycarbamide is very effective in reducing the rate of painful crises 13 
and  ACS in both adults and children (Charache, et al 1995, Olivieri and Vichinsky 14 
1998, Scott, et al 1996) and improves survival (Steinberg, et al 2003, Steinberg, et al 15 
2010). Therefore, hydroxycarbamide is the first line therapy for patients with frequent 16 
vaso-occlusive crises with transfusion being reserved for those who do not respond 17 
or in whom hydroxycarbamide is contraindicated. 18 
 19 
Recommendation 20 
Transfusion, either by simple or exchange transfusion, should be considered 21 
in patients with frequent painful episodes requiring hospital dmssion (more 22 
detail?) where hydroxycarbamide is ineffective or contraindicated (Grade 1B) 23 
 24 
5.4 Other possible indications 25 
Transfusion has been used in a variety of sickle cell related problems, where clinical 26 
experience or case reports/series have suggested benefit.  In patients with renal 27 
disease, transfusion may be considered in end stage renal disease, in those 28 
awaiting a renal transplant and post-renal transplant (Sharpe and Thein 2014). 29 
Transfusion has also been used in patients undergoing liver transplantation in the 30 




peri- transplant settings (Blinder, et al 2013, Gardner, et al 2014).   Blood transfusion 1 
in the treatment of pulmonary hypertension seems  theoretically reasonable with the 2 
aim of decreasing haemolysis and thereby nitric oxide scavenging and consequent 3 
pulmonary vasoconstriction and has been recommended for this purpose (Cho and 4 
Hambleton 2011, Machado and Gladwin 2005). 5 
 6 
The incidence of priapism and symptomatic avascular necrosis was significantly 7 
decreased by transfusion in the randomised SIT trial with incidence rate ratios of 8 
0.13 and 0.22, respectively (DeBaun, et al 2014), but its benefit in the management 9 
of patients with established disease has not been proven in randomised trials.  10 
 11 
Transfusion has been used for other conditions including leg ulcers (Delaney, et al 12 
2013, Minniti, et al 2010) and progressive sickle retinopathy (Gustave, et al 2013, 13 
McKinney, et al 2015). In some cases the reported benefit from transfusion has 14 
seemed dramatic, but specific recommendations must await more extensive data. 15 
 16 
Recommendation 17 
Transfusion for indications where evidence is limited should be based on a 18 
case-by-case assessment after full risk-benefit analysis (Grade 2C). 19 
 20 
6. PREOPERATIVE TRANSFUSION 21 
Anaesthesia and surgery increase sickle-related complications, particularly acute 22 
chest syndrome, while transfusion reduces the risk of perioperative complications 23 
(Howard, et al 2013, Vichinsky, et al 1995). Meticulous attention should be paid to 24 
optimising all aspects of perioperative care including oxygenation, hydration and  25 
warmth, as well as anaesthetic and surgical technique. Close liaison between 26 
anaesthetist, surgeon and haematologist is essential to ensuring good outcomes. 27 
Complicated surgical procedures should be undertaken in centres where there is 28 
specialist haemoglobinopathy support. 29 





With regards to transfusion, the two key questions to consider are: 2 
1. Should SCD patients be transfused routinely pre-operatively?  3 
2. If transfused, what is the optimal regimen? 4 
 5 
6.1 Role of routine preoperative transfusion 6 
This has long been controversial with insufficient randomised trial data impacting on 7 
variability in practice across hospitals in England (Buck, et al 2005) and in other 8 
studies (Table 2).  There have been advocates both of routine pre-operative 9 
transfusion (Bhattacharyya, et al 1993, Derkay, et al 1991, Fullerton, et al 1981, 10 
Janik and Seeler 1980) and selective transfusion (Bischoff, et al 1988, Fu, et al 11 
2005, Griffin and Buchanan 1993, Homi, et al 1979, Leff, et al 2007, Oduro and 12 
Searle 1972).  A large observational study showed that perioperative transfusion 13 
was associated with a significantly lower rate of SCD-related postoperative 14 
complications for SS patients undergoing low-risk procedures and for SC patients at 15 
all surgical risk levels (Koshy, et al 1995). However, these findings suggested that 16 
not all patients should routinely be transfused preoperatively. Another study showed 17 
that those receiving “no transfusion” suffered  the highest overall SCD-related 18 
complication rate (32%), chest syndrome rate (19%) and mortality rate (5%) but 19 
without significant difference between those randomised to aggressive or simple 20 
transfusion regimens (Haberkern, et al 1997) 21 
 22 
The most compelling evidence to support preoperative transfusion comes from the 23 
Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) trial (Howard, 24 
et al 2013). This was a randomised controlled trial in which a total of 67 SS and Sβo 25 
thalassaemia patients undergoing low risk surgery (e.g. adenoidectomy, dental 26 
procedures) and medium risk surgery (e.g. joint replacement, cholecystectomy, 27 
tonsillectomy) were randomly assigned to either no transfusion or transfusion 28 
(simple  transfusion if Hb<90 g/l, exchange transfusion if Hb ≥90 g/l to achieve 29 
estimated HbS <60%) (Howard, et al 2013). Classification of surgical risk was in 30 




accordance with the Cooperative Study of Sickle Cell Disease criteria (Koshy 1995). 1 
Significantly greater clinically important complications (39% v 15%) and serious 2 
adverse events (30% v 3%) were found in untransfused SS and S/βo-thalassaemia 3 
compared to transfused patients undergoing low-risk and medium-risk surgery. The 4 
most common serious adverse event was ACS accounting for 91% of all serious 5 
events occurring in 27% of untransfused patients compared with 3% in transfused 6 
patients. Intraoperative or postoperative transfusion was increased in the patients 7 
who had not been transfused preoperatively (Howard, et al 2013).  8 
 9 
Although the final number of subjects recruited into the trial at its termination was 10 
small, the TAPS study provided clear evidence to support preoperative transfusion in 11 
SS patients undergoing low-risk and medium-risk surgical procedures.  12 
 13 
6.2 Optimal preoperative transfusion regimen 14 
In a study by Vichinsky (Vichinsky, et al 1995) in SS and S/βo-thalassaemia patients, 15 
a top-up transfusion regimen to haemoglobin 100 g/l was reported to be as effective 16 
as exchange transfusion to attain haemoglobin 100 g/l and HbS <30% in preventing 17 
perioperative complications and was associated with a 50% lower risk of 18 
transfusion-related complications.  However, it must be noted that the type of 19 
exchange transfusion procedure was not described and some of the exchange 20 
transfused patients required repeated simple transfusion. Furthermore, in 14% of 21 
patients in the exchange transfusion arm, post-transfusion %HbS was substantially 22 
higher than the 30% target for a number of reasons including inadequate 23 
transfusion. Moreover, in the simple transfusion group, nearly 43% of the patients 24 
received “minimal transfusion therapy”. Despite these limitations, the authors 25 
concluded that simple transfusion was as effective as exchange transfusion.  26 
 27 
The issue of whether simple or aggressive transfusion had better outcomes was not 28 
addressed in the TAPS trial where the transfusion regimen was either simple  29 
transfusion if Hb <90 g/l or partial exchange transfusion if Hb ≥90 g/l, to a target Hb 30 




of 100 g/l and estimated HbS <60% (Howard, et al 2013).  Seventy-six percent of 1 
transfused patients received simple transfusion, providing support for the efficacy of 2 
a conservative transfusion regimen in reducing post-operative complications for the 3 
relevant surgical procedures reported in the trial. 4 
 5 
It is not possible to give dogmatic guidelines regarding the choice of type of 6 
preoperative transfusion and transfusion targets; these should be tailored to the 7 
individual patient, taking into account factors such as the type of surgery, the 8 
severity of the patient’s sickle cell disease and co-morbidities (see section 6.5). 9 
However, it is reasonable to undertake simple transfusion for low and moderate risk 10 
surgery if Hb is <90 g/l to achieve a post-transfusion Hb of 100 g/l. An exchange 11 
transfusion should be considered for patients undergoing high risk surgery, patients 12 
with severe sickle cell disease and those with significant co-morbidities.  13 
 14 
6.3 Emergency surgery 15 
Evidence for the role of transfusion in emergency surgery is very limited. In the 16 
largest study on surgery in SCD, 717 patients underwent 1079 surgical procedures 17 
of which 271 (25%) were emergency procedures (Koshy, et al 1995). When all 18 
procedures (elective + emergency) were considered, most patients undergoing 19 
cholecystectomy and splenectomy were transfused preoperatively (94% of SS and 20 
82% of SC) as were those undergoing Caesarean section or hysterectomy (91% of 21 
SS and 72% of SC). As the data for postoperative outcomes were analysed together 22 
for elective and emergency procedures (rather than separately), it is not possible to 23 
assess the effect on transfusion on outcomes for SCD patients undergoing 24 
emergency surgery in this study. 25 
 26 
Similarly, in another observational study, no separate analyses were carried for 27 
patients undergoing emergency surgery (Bischoff, et al 1988). In a further 28 
retrospective study where perioperative transfusion was used selectively and 29 
sparingly (Homi, et al 1979) 5 postoperative deaths occurred in 28 patients 30 




undergoing emergency surgery; however, it is not clear if these patients were 1 
transfused preoperatively.  2 
 3 
The important principle here is to not unnecessarily delay emergency surgery 4 
because of transfusion. A reasonable policy is to give a simple transfusion to 5 
patients who have Hb <90 g/l and then proceed to surgery with minimal delay. If the 6 
Hb is >90 g/l and the surgical procedure is low risk, it is reasonable to proceed to 7 
surgery without delay while arrangements are made to transfuse the patient intra- 8 
operatively or post-operatively if necessary. 9 
 10 
6.4 Role of transfusion in surgery for sickle genotypes other than SS 11 
There is a paucity of evidence relating specifically to SC and other sickle genotypes. 12 
One observational study suggested a benefit for transfusion in reducing the 13 
incidence of sickle cell-related postoperative complications for SC patients at all 14 
levels of surgical risk (Koshy, et al 1995), however,  transfused SC patients 15 
undergoing low-risk surgery had higher rates of non-sickle cell postoperative 16 
complications (fever and bleeding) than untransfused patients.  A further study 17 
demonstrated that preoperative transfusion was beneficial for  moderate risk 18 
procedures, particularly abdominal surgery (Neumayr, et al 1998).  19 
 20 
6.5 Deciding which patients may benefit from preoperative transfusion.  21 
The TAPS trial has provided evidence for the efficacy of preoperative transfusion 22 
only for SS patients with preoperative Hb 60-90 g/l undergoing a narrow range of 23 
elective medium-risk surgical procedures (Howard, et al 2013). The trial’s findings 24 
may not be applicable to many other surgical situations. However, on the basis of the 25 
findings, it is recommended that preoperative transfusion to an Hb of 100 g/l be 26 
considered a standard intervention in SS undergoing elective low-risk or medium-risk 27 
surgery as defined in the study (Howard, et al 2013). For other patients it is 28 
recommended that each case is judged on its own merits in consultation with the 29 
SHT. Transfusion should be considered when the risk of post-operative chest 30 




infection or ACS is high, but this has yet to be clearly shown in prospective trials. 1 
Transfusion is also recommended for individuals with significant co-morbidities (e.g. 2 
abnormal pulmonary, cardiac, renal and hepatic function) and  in those undergoing 3 
high-risk surgical procedures or having lengthy surgical procedures (Wun 2009).  4 
 5 
The optimal method of transfusion remains an open question but currently available 6 
evidence indicates that simple transfusion is not inferior to exchange transfusion  in 7 
low- to medium-risk surgery   (Howard, et al 2013, Vichinsky, et al 1995), However 8 
exchange transfusion is recommended for patients undergoing high-risk surgery, 9 
although this has not been directly addressed in studies.  10 
 11 
Recommendation 12 
Preoperative transfusion (simple transfusion to Hb 100 g/l if Hb <90 g/l or 13 
partial exchange if Hb ≥90 g/l) is recommended for SS patients undergoing low 14 
and medium-risk surgery (Grade 1A). 15 
 16 
Exchange transfusion is recommended for all patients with SS requiring high-17 
risk surgery (Grade 1C). 18 
 19 
Preoperative transfusion is recommended for patients with SC undergoing 20 
moderate risk surgery and high risk surgery (Grade 1C). 21 
 22 
All other patients undergoing surgery should be individually assessed taking 23 
into account previous history and complexity of surgery and a management 24 
plan should be formulated to include the need for transfusion (Grade 1C). 25 
 26 
For patients requiring emergency surgery, the urgency and complexity of the 27 
procedure should be taken into account in the timing of perioperative 28 
transfusion.  Provided transfusion will not result in undue delay to surgery, 29 
simple transfusion should be given preoperatively to a target Hb of 100 g/l if 30 
the Hb is low. If Hb ≥90 g/l and surgical risk is low but transfusion will result in 31 
an unacceptable delay to surgery, it is reasonable to proceed to surgery 32 




without delay while arrangements are made to transfuse the patient intra- 1 
operatively or post-operatively if necessary (Grade 1C). 2 
 3 
 4 
7. TRANSFUSION IN PREGNANCY 5 
Sickle cell disease in pregnancy is associated with an increased risk of both 6 
maternal and fetal complications (Serjeant, et al 2004, Smith, et al 1996, Villers, et al 7 
2008). Maternal complications include sickle-related problems (notably painful crises, 8 
acute chest syndrome) and pregnancy-related syndromes such as pre-eclampsia, 9 
pre-term labour and an increased rate of Caesarean section (Villers, et al 2008). 10 
Fetal complications include intra-uterine growth restriction, prematurity and 11 
increased rates of fetal loss (Serjeant, et al 2004).   In a UK-wide observational study 12 
of 109 pregnancies in SCD, 52.3% suffered painful crises during pregnancy and 13 
12.8% within six weeks post-partum; 6.4% had ACS and 21.1% were admitted to 14 
intensive care in the peripartum period (Oteng-Ntim, et al 2014). 15 
 16 
There is a single prospective randomised controlled study which compared 36 17 
pregnant SS women who were transfused prophylactically (simple  or partial 18 
exchange transfusion commencing in first or second trimester; target Hb 100-110 g/l; 19 
target HbS <35%) to a control group of 36 SS women who received transfusion only 20 
for medical or obstetric emergencies (Koshy, et al 1988). This study found a 21 
significant reduction in the incidence of painful crises and substantial decrease in 22 
other SCD-related complications in the group receiving prophylactic transfusions but 23 
no difference in medical and obstetric complications or fetal outcome between the 24 
two groups. Additionally, satisfactory pregnancy outcomes were observed in a non-25 
randomised group of SS, SC and S/β thalassaemia women who were transfused 26 
only for medical or obstetric emergencies. In view of these results, the authors 27 
concluded that omitting prophylactic transfusions was not harmful to pregnant 28 
patients with SCD or their offspring and thus routine use of transfusions in pregnancy 29 
was not justified. However, this study had a number of significant limitations 30 
including small sample size and high risk of bias (Malinowski, et al 2015).  31 
 32 




Other uncontrolled studies have shown conflicting evidence with some showing 1 
evidence for a benefit of transfusion (Asma, et al 2015, Benites, et al 2015, 2 
Cunningham, et al 1983, Gilli, et al 2007, Howard, et al 1995, Morrison, et al 1991) 3 
whilst others did not (El-Shafei, et al 1995, Tuck, et al 1987). The study by Howard 4 
demonstrated a trend for reduced SCD-related complications in the third trimester in 5 
patients on prophylactic exchange transfusions, leading the authors to recommend 6 
prophylactic transfusions from the 26th week of pregnancy onwards in SS patients 7 
(Howard, et al 1995). In a more recent retrospective study, high rates of painful 8 
sickle crises and other severe sickle complications occurred despite a policy of 9 
prophylactic partial exchange transfusions to maintain HbS <40% from 22-26 weeks 10 
onwards for all sickle patients  (Ngo, et al 2010), but there was no control arm not 11 
receiving prophylactic transfusion for comparison.  12 
 13 
A Cochrane review which examined evidence from two small studies of low quality 14 
concluded that other than a marginal reduction in the rate of painful crises, 15 
prophylactic transfusion conferred no clear advantage over selective transfusion with 16 
regards to pregnancy outcome (Okusanya and Oladapo 2013). However, the 17 
findings of a more recent systematic review and meta-analysis which included 11 18 
cohort studies and the RCT by Koshy et al  (Koshy, et al 1988) suggested that 19 
prophylactic transfusion is associated with a reduction in vaso-occlusive episodes, 20 
maternal mortality, overall pulmonary complications, neonatal mortality and pre-term 21 
birth while acknowledging the methodological limitations of the original study designs 22 
(Malinowski, et al 2015).  23 
 24 
As a result of the limited and sometimes conflicting data, the use of prophylactic 25 
transfusion varies between centres.  There is a consensus however that pregnant 26 
women with a history of severe SCD-related complications such as recurrent ACS, 27 
and stroke, individuals on chronic transfusion prior to pregnancy, and those with 28 
repeated sickle cell crises or exacerbation of anaemia during pregnancy should 29 
receive transfusion (Koshy 1995, RCOG 2011, Sickle Cell Society 2008).  30 
Prophylactic transfusion should also be considered for women with other serious 31 




medical or obstetric conditions   or with a multiple pregnancy.   (ACOG 2007, Koshy 1 
1995, RCOG 2011).  2 
 3 
It should be emphasised that pregnancy in women with SCD is high-risk and expert 4 
obstetric care is essential to achieving good outcomes. The ideal standard of care is 5 
joint management by obstetricians and haematologists who are experienced in the 6 





Transfusion is not routinely required for uncomplicated singleton pregnancies, 12 
but should be considered for women at high risk of with sickle complications 13 
during pregnancy (painful crises, acute chest syndrome, stroke etc.) (Grade 14 
1B). 15 
 16 
Prophylactic Transfusion should be considered in women with previous or 17 
current serious medical (such as chest synrome), obstetric or fetal problems, 18 
women with worsening anaemia, those on long-term transfusions for stroke 19 
prevention or for amelioration of severe sickle complications, women on 20 
hydroxycarbamide because of severe disease and those with a multiple 21 
pregnancy (Grade 1C). 22 
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